Pulmonary hypertension is a life-threatening illness with debilitating physical and emotional consequences. The progression of this devastating disease is characterized by a continuous increase in pulmonary vascular resistance, which results in elevated pulmonary artery pressure and leads to right heart failure. Treatment is focused on targeting the underlying complex etiology via the endothelin, prostacyclin, and nitric oxide (NO) pathways. Emergence of new treatments over the past 2 decades has led to improvement in the functional status and time to clinical worsening. Even with recent advances, outcomes remain suboptimal. Phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, were approved for treatment of pulmonary arterial hypertension (PAH) by the Food and Drug Administration (FDA) in 2005, which holds promise in improving quality of life and therefore making this class of medications effective palliative therapy agents. In this review, we summarize the emergence of sildenafil as a treatment for PAH and its role as palliative therapy.
Isolated ventricular noncompaction (IVNC) occurs because of interruption of trabecular morphogenesis in the myocardium leading to ventricular noncompaction. Patients present with heart failure or with systemic complications secondary to thromboembolism or arrhythmias. High index of suspicion is necessary for early diagnosis. We present a case of 48-year-old male with unexplained recurrent syncope who was eventually diagnosed with IVNC.
Introduction:
Bivalirudin and heparin are the two most commonly used anticoagulants
used during Percutaneous Coronary Intervention (PCI). The results of Randomized Controlled
Trials (RCTs) comparing bivalirudin versus heparin monotherapy in the era of radial access are
controversial, questioning the positive impact of bivalirudin on bleeding. The purpose of this
systematic review is to summarize the results of RCTs comparing the efficacy and safety of
bivalirudin versus heparin with or without Glycoprotein IIb/IIIa Inhibitors (GPI).
Methods:
This systematic review was performed in accordance with Preferred Reporting Items for
Systematic Reviews and Meta-Analyses PRISMA statements for reporting systematic reviews. We
searched the National Library of Medicine PubMed, Clinicaltrial.gov and the Cochrane Central
Register of Controlled Trials to include clinical studies comparing bivalirudin with heparin in
patients undergoing PCI. Sixteen studies met inclusion criteria and were reviewed for the summary.
Findings:
Several RCTs and meta-analyses have demonstrated the superiority of bivalirudin over
heparin plus routine GPI use in terms of preventing bleeding complications but at the expense of
increased risk of ischemic complications such as stent thrombosis. The hypothesis of post- PCI
bivalirudin infusion to mitigate the risk of acute stent thrombosis has been tested in various RCTs
with conflicting results. In comparison, heparin offers the advantage of having a reversible agent, of
lower cost and reduced incidence of ischemic complications.
Conclusion:
Bivalirudin demonstrates its superiority over heparin plus GPI with better clinical
outcomes in terms of less bleeding complications, thus making it as anticoagulation of choice
particularly in patients at high risk of bleeding. Further studies are warranted for head to head
comparison of bivalirudin to heparin monotherapy to establish an optimal heparin dosing regimen
and post-PCI bivalirudin infusion to affirm its beneficial effect in reducing acute stent thrombosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.